How should sacubitril/valsartan (Entresto) be initiated in a patient with diastolic heart failure, including starting dose, ACE‑inhibitor washout period, blood pressure, potassium, renal function criteria, and titration plan?

Entresto Initiation in Diastolic Heart Failure

Do not initiate Entresto in patients with diastolic heart failure (HFpEF) unless they have reduced ejection fraction (HFrEF). The evidence and FDA approval for sacubitril/valsartan is primarily established for heart failure with reduced ejection fraction, not isolated diastolic dysfunction.

Critical Pre-Initiation Assessment

However, if your patient has HFrEF (not pure diastolic HF), here's the specific protocol:

Mandatory Washout Period

• Stop any ACE inhibitor 36 hours before starting Entresto 1
• This washout is non-negotiable to prevent angioedema risk
• ARBs do not require washout

Pre-Treatment Checklist

Blood Pressure Requirements:

• Systolic BP ≥100 mmHg is the threshold used in trials 2
• If SBP 100-110 mmHg: Use conservative 6-week titration (not 3-week) 2
• If SBP >110 mmHg: Standard titration acceptable
• Asymptomatic hypotension alone is not a contraindication

Renal Function:

• eGFR ≥30 mL/min/1.73 m² required for initiation 3
• Creatinine <2.5 mg/dL (<221 μmol/L) 4
• Important caveat: If eGFR drops below 30 during treatment, continuation is safe and beneficial 5

Potassium:

• Serum K+ <5.0-5.2 mmol/L 6
• Avoid potassium-sparing diuretics during initiation 7

Volume Status:

• Patient should be hemodynamically stable
• Preferably "wet" (still congested) for better tolerability 8
• Avoid excessive diuresis in the 24 hours before starting 7

Dosing Protocol

Standard Starting Dose

49/51 mg twice daily 1

Reduced Starting Dose (24/26 mg twice daily) if:

• Not currently on ACE inhibitor or ARB 1
• Previously on low-dose ACE inhibitor/ARB 1
• Severe renal impairment (eGFR 30-60) 1
• Moderate hepatic impairment 1
• SBP 100-110 mmHg (use clinical judgment) 2

Very low dose option (25 mg twice daily): While not FDA-approved, real-world evidence supports this in patients with baseline SBP ~103 mmHg who would otherwise not receive therapy 9

Titration Schedule

Standard Titration

• Week 0: 49/51 mg twice daily
• Week 2-4: Double to 97/103 mg twice daily (target dose) 1
• Check BP, renal function, and electrolytes 1-2 weeks after each dose change 7

Conservative Titration (for borderline BP or renal function)

• Week 0: 24/26 mg twice daily
• Week 2: 49/51 mg twice daily
• Week 5: 97/103 mg twice daily 10

The conservative approach achieved 84% target dose attainment vs 78% with rapid titration in patients on low-dose ACEI/ARB 10.

Monitoring Protocol

Initial monitoring (first 2-3 days):

• Blood pressure
• Potassium (especially if on MRA)
• Creatinine 6

After each dose increase:

• BP, K+, creatinine at 1-2 weeks 7, 1

Ongoing:

• Monthly for first 3 months
• Then every 6 months 7

Common Pitfalls to Avoid

1. Don't stop for asymptomatic hypotension - only symptomatic hypotension requires intervention 4

2. Don't avoid NSAIDs completely - counsel patients to avoid OTC NSAIDs, but prescribed NSAIDs may be necessary 7, 3

3. Don't discontinue if eGFR drops below 30 - continuation is safe and maintains benefit 5

4. Don't reduce diuretics too aggressively - Entresto initiation may require diuretic adjustment, but maintain euvolemia 8, 3

5. Don't forget the 36-hour ACE inhibitor washout - this is the most critical safety step 1

Expected Outcomes

• NT-proBNP reduction evident within weeks 6, 9
• Renal function typically improves or stabilizes, even in patients with baseline eGFR 30-60 11, 12
• Left atrial size reduction (unique benefit vs valsartan alone) 13
• Symptomatic improvement within weeks to months 4

Special Populations

Acute decompensated HF (inpatient initiation):

• Safe to initiate before discharge in hemodynamically stable patients 14, 6
• PIONEER-HF showed safety in hospitalized patients
• May simplify management vs initiating ACE inhibitor first then switching 14

Renal dysfunction (eGFR 30-60):

• Start at 24/26 mg twice daily 1
• Expect greater eGFR improvement than in patients without renal dysfunction 11
• Higher rates of hyperkalemia (16.3% vs 6.5%) but manageable 11